Research programme: small molecule therapeutics - NeuShen Therapeutics
Latest Information Update: 01 Sep 2023
At a glance
- Originator NeuShen Therapeutics
- Class Antidementias; Antidepressants; Antiparkinsonians; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Major depressive disorder; Parkinson's disease
Most Recent Events
- 01 Sep 2023 Early research in Alzheimer's disease in USA, China (unspecified route), prior to September 2023 (Neushen pipeline September 2023)
- 01 Sep 2023 Early research in Major depressive disorder in China, USA (unspecified route), prior to September 2023 (Neushen pipeline September 2023)
- 01 Sep 2023 Early research in Parkinson's disease in USA, China (unspecified route), prior to September 2023 (Neushen pipeline September 2023)